Name: SS-31 50mg
Brand: RetaLABS.is
SKU: ss-31-50mg

Question 1

Why choose SS-31 50mg over the 10mg vial?

Accepted Answer

The 50mg vial provides a significantly lower cost per milligram, which is particularly relevant for SS-31 (a peptide with a complex synthesis (D-Arg, Dmt modification, C-terminal amide) that commands a premium price per milligram compared to simple linear peptides. At the same quality specification, selecting the 50mg format can reduce the per-dose research cost substantially for extended programmes. Beyond cost, single-batch supply ensures that all experimental sessions in a research programme use material from the same production run) eliminating any potential inter-batch variability in purity, D-Arg content, or Dmt oxidation state as a source of experimental noise. For multi-cohort or multi-timepoint studies where a fixed preparation needs to remain constant across months of work, the 50mg vial provides sufficient material in a single unit. Researchers managing multiple subjects or extended protocols benefit from fewer procurement events and reduced risk of supply interruption mid-protocol.

Question 2

What is SS-31 used for in research?

Accepted Answer

SS-31 (Elamipketide; D-Arg-Dmt-Lys-Phe-NH₂) is a mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane through electrostatic interaction with cardiolipin. Its primary research utility lies in models of mitochondrial dysfunction, where it stabilises cardiolipin structure, preserves cristae morphology, reduces reactive oxygen species generation at the electron transport chain, and prevents cytochrome c release during apoptotic signalling. The spectrum of research models in which SS-31 has been investigated is broad: cardiac ischaemia-reperfusion injury, heart failure with preserved ejection fraction (HFpEF), skeletal muscle sarcopenia and exercise-related mitochondrial fatigue, cisplatin-induced renal nephrotoxicity, and age-related mitochondrial decline across multiple organ systems. SS-31 has also entered human clinical trials for some of these indications, providing a wealth of published pharmacokinetic and pharmacodynamic data that researchers can draw on to contextualise preclinical findings. Its unique targeting mechanism, combined with both structural and antioxidant protective functions, makes SS-31 one of the most well-characterised mitochondria-targeted peptides available for research.

Question 3

How should the 50mg vial be managed for extended research?

Accepted Answer

For extended research protocols using the 50mg vial, the most effective strategy is to keep the bulk lyophilised and frozen at −20°C and perform periodic partial reconstitutions as needed. When a new research session begins, remove the lyophilised vial from freezer storage, allow it to equilibrate to room temperature briefly, and reconstitute only the volume required for the current session or a session block of two to four weeks. Reconstituted SS-31 solution should be stored at 2–8°C and used within four weeks. Once this window is approaching, prepare a fresh aliquot from the still-frozen lyophilised vial. For protocols requiring even more granular control (for example, where you need to ensure each experimental day uses material of identical age from reconstitution) prepare single-session aliquots from a single reconstitution event, freeze at −20°C immediately, and thaw one per session. This minimises cumulative exposure of any given aliquot to degradation conditions while maintaining convenience.

Question 4

Is there a difference in quality between the 10mg and 50mg formats?

Accepted Answer

No. Both the 10mg and 50mg SS-31 formats are sourced from the same manufacturer and produced under identical synthesis conditions (including the D-arginine incorporation, dimethyltyrosine modification, and C-terminal amide protection that define the SS-31 structure). The same quality release specifications apply to both formats: mass confirmation by LCMS and visual inspection for clarity. There is no economy versus premium quality distinction between different vial sizes in this product range. Researchers sometimes express concern about this point because in some markets, bulk-format peptides are produced to looser specifications. That is not the case here. If you are comparing experimental results between a study that used 10mg vials and one that used 50mg vials, you can treat the SS-31 quality as equivalent across both, provided both are within expiry and have been handled under the same storage conditions.

SS-31 50mg

Customer Reviews

Frequently Asked Questions